Registration Now | The GenScript Biotech Global Forum 2024
Introduction
Gene and cell therapy is booming worldwide, fueled by major innovations in life science and medicine and funding from global capital markets. To advance this crucial field, GenScript convenes top scientists and industry leaders from around the world, concurrent with the annual JP Morgan Healthcare Conference. The upcoming GenScript Biotech Global Forum 2024 will take place at the Grand Hyatt in San Francisco on Wednesday, January 10, 2024.
Under the theme Innovations and breakthroughs shaping tomorrow's cell and gene therapies, GenScript is inviting gene and cell therapy thought leaders from the research, industry, and capital communities as well as representatives from regulatory bodies to focus on recent developments in research, technological breakthroughs, commercialization challenges, and regulatory trends. We are looking forward to hosting thought leaders from around the world, united in the pursuit of cures to help more patients.
We would like to extend to you a cordial invitation to join your peers at this important event in San Francisco in January 2024.
- Free code:Mybio2024
- Registration deadline: November 20th
- Link to register: www.eventbrite.com/e/722590306057?aff=oddtdtcreator
- Scan the QR code to register:
Hot Topics
- Genome Editing: Progress & Opportunities
- CAR-T Leaders Drive GCT Commercialization
- Next-generation Gene Therapy
- What Lies Ahead for GCT Commercialization Amid Funding Frenzy
- Policy and Latest Regulatory Trends in GCT
- IND Filing for GCT Products
Confirmed Speakers
- David Liu, Professor at the Broad Institute, Harvard University & HHMI
- Ying Huang, CEO, Legend Biotech
- Michael Bowen, Chief Scientist, Oncology Cell Therapy Development, AstraZeneca
- Simone Fishburn, Editor in Chief, BioCentury
- Adrian Bot, CSO and EVP R&D, Capstan Therapeutics
- Devyn Smith, CEO,Arbor Biotech
- Stanley Qi, Scientific Founder, Epic Bio
- Alex Goraltchouk, COO, Remedium Bio
- Konstantinos Aprilakis, Partner, Deerfield Management
- Yi Shi, Founder and Managing Partner, Lilly Asia Ventures
- Josh Resnick, Senior Managing Director, RA Capital Management
- John Mendlein, Executive Partner, Flagship Pioneering
- More to be confirmed …..
LIMITED SEATS AVAILABLE!
Register with the code
Mybio2024 before
November 20th to
save Your ComplimentaryPass. Join us in San Francisco at what promises
to be a unique opportunity to shareinsights and collaborate on the
global advancement of cell and gene therapy!
CONTACT US: [email protected]
最新评论
推荐文章
作者最新文章
你可能感兴趣的文章
Copyright Disclaimer: The copyright of contents (including texts, images, videos and audios) posted above belong to the User who shared or the third-party website which the User shared from. If you found your copyright have been infringed, please send a DMCA takedown notice to [email protected]. For more detail of the source, please click on the button "Read Original Post" below. For other communications, please send to [email protected].
版权声明:以上内容为用户推荐收藏至CareerEngine平台,其内容(含文字、图片、视频、音频等)及知识版权均属用户或用户转发自的第三方网站,如涉嫌侵权,请通知[email protected]进行信息删除。如需查看信息来源,请点击“查看原文”。如需洽谈其它事宜,请联系[email protected]。
版权声明:以上内容为用户推荐收藏至CareerEngine平台,其内容(含文字、图片、视频、音频等)及知识版权均属用户或用户转发自的第三方网站,如涉嫌侵权,请通知[email protected]进行信息删除。如需查看信息来源,请点击“查看原文”。如需洽谈其它事宜,请联系[email protected]。